Mechanism of Action of Etoposide

Introduction

Etoposide is a semisynthetic podophyllotoxin derivative widely used as an antineoplastic agent in the treatment of various solid tumors and hematological malignancies. It is a cell cycle–specific drug, acting primarily during the S and G₂ phases. Etoposide is high-yield for pharmacology and oncology examinations due to its unique enzyme target, characteristic DNA damage mechanism, and dose-limiting myelosuppression.


MOA of Etoposide
Etoposide pharmacology
Mechanism of action of drugs flowchart
Etoposide mechanism of action flowchart

Mechanism of Action (Step-wise)

Etoposide induces cytotoxicity by interfering with DNA replication and repair.

Step 1: Entry into proliferating cells
Etoposide preferentially affects rapidly dividing cells undergoing DNA synthesis.

Step 2: Targeting topoisomerase II
It binds to and inhibits topoisomerase II, an enzyme responsible for relieving torsional strain in DNA by creating transient double-strand breaks.

Step 3: Stabilization of DNA–enzyme complex
Etoposide stabilizes the cleavable complex formed between topoisomerase II and DNA.

Step 4: Prevention of DNA re-ligation
The drug prevents re-ligation of double-strand DNA breaks created by topoisomerase II.

Step 5: Accumulation of DNA damage
Persistent DNA strand breaks lead to inhibition of DNA replication and transcription.

Step 6: Cell cycle arrest and apoptosis
DNA damage triggers cell cycle arrest in the S and G₂ phases, followed by apoptosis.

Exam pearl:
Etoposide causes double-strand DNA breaks, unlike topoisomerase I inhibitors which cause single-strand breaks.


Pharmacokinetics

  • Route of administration: Oral, IV
  • Oral bioavailability: ~50% (variable)
  • Protein binding: ~95%
  • Distribution: Widely distributed; limited CNS penetration
  • Metabolism: Hepatic (partly via CYP3A4)
  • Half-life: 6–12 hours
  • Excretion: Renal and biliary
  • Dose adjustment: Required in renal impairment

Clinical Uses

  • Testicular cancer (part of BEP regimen)
  • Small cell lung cancer
  • Lymphomas (Hodgkin and non-Hodgkin)
  • Acute myeloid leukemia (selected regimens)
  • Ovarian cancer
  • Ewing sarcoma and other solid tumors

Etoposide is commonly used in combination chemotherapy to enhance efficacy and reduce resistance.


Adverse Effects

Hematological (dose-limiting):

  • Myelosuppression (leukopenia > thrombocytopenia)

Gastrointestinal:

  • Nausea
  • Vomiting
  • Mucositis

Dermatological:

  • Alopecia

Cardiovascular:

  • Hypotension (rapid IV infusion)

Long-term risk:

  • Secondary acute leukemia (therapy-related AML)

Comparative Analysis

Etoposide vs Doxorubicin vs Irinotecan

FeatureEtoposideDoxorubicinIrinotecan
Primary targetTopoisomerase IITopoisomerase II + free radicalsTopoisomerase I
DNA damageDouble-strand breaksDouble-strand breaksSingle-strand breaks
Cell cycle specificityS, G₂ phaseCell cycle–nonspecificS phase
Major toxicityMyelosuppressionCardiotoxicityDiarrhea
Secondary leukemia riskYesYesNo

Explanation:
Etoposide selectively inhibits topoisomerase II, causing irreversible DNA double-strand breaks. Irinotecan targets topoisomerase I, while doxorubicin additionally generates free radicals, explaining differences in toxicity profiles.


MCQs

  1. Etoposide primarily inhibits which enzyme?
    a) DNA polymerase
    b) Topoisomerase I
    c) Topoisomerase II
    d) RNA polymerase

Answer: c) Topoisomerase II

  1. DNA damage caused by etoposide involves:
    a) Single-strand breaks
    b) Double-strand breaks
    c) DNA cross-linking
    d) Base alkylation

Answer: b) Double-strand breaks

  1. Etoposide is most active in which cell cycle phases?
    a) G₁ phase
    b) S and G₂ phases
    c) M phase
    d) G₀ phase

Answer: b) S and G₂ phases

  1. Dose-limiting toxicity of etoposide is:
    a) Nephrotoxicity
    b) Neurotoxicity
    c) Myelosuppression
    d) Cardiotoxicity

Answer: c) Myelosuppression

  1. Etoposide is a derivative of:
    a) Vinca alkaloids
    b) Taxanes
    c) Podophyllotoxin
    d) Nitrosoureas

Answer: c) Podophyllotoxin

  1. Which malignancy commonly uses etoposide?
    a) Breast cancer
    b) Small cell lung cancer
    c) Colon cancer
    d) Thyroid cancer

Answer: b) Small cell lung cancer

  1. Risk of secondary leukemia with etoposide is due to:
    a) Alkylation of DNA
    b) DNA cross-linking
    c) Chromosomal translocations
    d) Folate depletion

Answer: c) Chromosomal translocations

  1. Rapid IV infusion of etoposide may cause:
    a) Hypertension
    b) Bradycardia
    c) Hypotension
    d) Arrhythmia

Answer: c) Hypotension

  1. Etoposide differs from irinotecan because it inhibits:
    a) Topoisomerase I
    b) Topoisomerase II
    c) Microtubules
    d) DNA methylation

Answer: b) Topoisomerase II

  1. Alopecia caused by etoposide is due to:
    a) Neuronal toxicity
    b) Bone marrow failure
    c) Damage to rapidly dividing cells
    d) Hormonal imbalance

Answer: c) Damage to rapidly dividing cells


FAQs

1. Why is etoposide cell cycle specific?
Because it acts during DNA synthesis and repair phases.

2. What type of DNA breaks does etoposide cause?
Double-strand DNA breaks.

3. Can etoposide cross the blood–brain barrier?
No, CNS penetration is limited.

4. Why is secondary leukemia a concern?
Due to chromosomal damage from topoisomerase II inhibition.

5. Is etoposide used alone?
Usually in combination chemotherapy regimens.


References

Leave a Comment

PRO
Ad-Free Access
$3.99 / month
  • No Interruptions
  • Faster Page Loads
  • Support Content Creators